pH Deregulation as the Eleventh Hallmark of Cancer - Tapa blanda

Acerca de los autores

Tomas Koltai is Board Certified Specialist in Medical Oncology (1985), PhD in Chemistry (1997) and Master’s in Sciences in Molecular Oncology, University of Buenos Aires (2011). He has vast experience on cancer treatment at several positions: staff oncologist, Sanatorio Mater Dei, Argentina (1985-1990); Head of Oncology, Central Hospital of the Centro Gallego de Buenos Aires (1990-2000) and Medical Director, at the same institution (2000-2002); Head of the Department of Chemotherapy, National Social Services for Retirees, Argentina (2002-2014); Head of the Department of Oncology, Social Services of the National Food Workers Union, Argentina (2010-2014) and Medical Director at the same institution (2014-2016). He has authored several seminal publications on cancer and created the new “triple-edged cancer treatment”.

Research in Dr. Fliegel’s laboratory investigates membrane proteins’ function, how intracellular pH is regulated and the role of Na+/H+ exchanger in human disease, especially heart disease and breast cancer. The work is funded by CIHR and other sources. Dr. Fliegel has published over 150 publications in numerous journals including J. Biological Chemistry, J. Molecular and Cellular Cardiology, Hypertension, Cancer Research, Basic Research in Cardiology and others. He has authored two books and served on several editorial boards of Journals and grant panels such as CIHR. His awards include a Killam Annual Professor Award (2009-10), a Tier one Basic Science Mentoring Award (2013), McCalla Research Professorship Award (2007) and Alberta Heritage Foundation for Medical Research Scientist Award (2006-2013).

Stephan Reshkin, PhD, is molecular biologist and Associate Professor at the University of Bari (Italy). Dr. Reshkin has published 108 scientific papers, several book chapters and co-authored An Innovative Approach to Understanding and Treating Cancer: Targeting pH (Elsevier, 2020). His main research interests are cancer cell and pancreatic ductal adenocarcinoma.

Fátima Baltazar holds a degree in Pharmaceutical Sciences by the University of Coimbra (Portugal, 1991), a PhD by the University of Hull (UK, 1998) and has postdoctoral experience at the University of Minho (Portugal, 1998-2003). She is currently Associate Professor at the Medical School of University of Minho (Portugal). Fatima joined ICVS (Life and Health Sciences Research Institute) team in 2004 and she is currently Principal Investigator and Coordinator of the Surgical Sciences Research Domain (SSRD). She started her research on the Cancer field in 2005 and, in the last years, Fatima’s main research interest has been on cancer metabolism, focusing on the discovery of new prognostic metabolic biomarkers and cancer therapeutic targets, using human samples and suitable in vitro and in vivo cancer models. Fátima has published 104 international peer-reviewed research articles, 8 book chapters and she is also (co-)inventor on two national patent applications.

Rosa Angela Cardone is currently Assistant Professor at the Department of Bioscience, Biotechnologies and Biopharmaceutics, Section of Physiology, University of Bari, Italy. She has a long-standing expertise in the pH deregulation and has extensively investigated its role in tumor transformation and malignancy.

De la contraportada

pH Deregulation as the Eleventh Hallmark of Cancer presents key concepts about pH deregulation in a concise and straight-forward manner. pH deregulation can improve the outcome of classical treatments without adding toxicity to them, and the book shows that treating the pH peculiarities of cancer is simple and can be performed with existing drugs. Based on the classification of tumor malignancy in ten hallmarks, the authors put pH deregulation at the spotlight and separated from metabolic reprogramming due to its impact on all other hallmarks, proposing it as an additional characteristic to evaluate and fight cancer.

The book discusses topics such as pH regulation and metabolism, sodium hydrogen exchanger, monocarboxylate transporter, V-ATPase proton pump, carbonic anhydrases, and voltage gated sodium channels. In addition, it discusses clinical and therapeutic implications, and future perspectives.

It is a valuable resource for researchers, oncologists, students and members of the biomedical and medical fields who want to learn more about the role of pH deregulation in cancer treatment.